These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 18929119

  • 1. Clinical trials in neuroprotection.
    Whitcup SM.
    Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM, Ravina B.
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F, Olanow CW.
    Ann Neurol; 2003 Apr; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders?
    Haefliger IO, Fleischhauer JC, Flammer J.
    Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotection: extrapolating from neurologic diseases to the eye.
    Danesh-Meyer HV, Levin LA.
    Am J Ophthalmol; 2009 Aug; 148(2):186-191.e2. PubMed ID: 19464671
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glaucoma as a neurodegenerative disease.
    Gupta N, Yücel YH.
    Curr Opin Ophthalmol; 2007 Mar; 18(2):110-4. PubMed ID: 17301611
    [Abstract] [Full Text] [Related]

  • 11. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O.
    Neurology; 2009 Feb 17; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [Abstract] [Full Text] [Related]

  • 12. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K.
    Ann Neurol; 2003 Feb 17; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Application of MRS to mouse models of neurodegenerative illness.
    Choi JK, Dedeoglu A, Jenkins BG.
    NMR Biomed; 2007 May 17; 20(3):216-37. PubMed ID: 17451183
    [Abstract] [Full Text] [Related]

  • 17. Challenges in the development of glaucoma neuroprotection therapy.
    Liu Y, Pang IH.
    Cell Tissue Res; 2013 Aug 17; 353(2):253-60. PubMed ID: 23474740
    [Abstract] [Full Text] [Related]

  • 18. Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study.
    Dykens JA, Moos WH, Howell N.
    Ann N Y Acad Sci; 2005 Jun 17; 1052():116-35. PubMed ID: 16024755
    [Abstract] [Full Text] [Related]

  • 19. Neuroprotection and neurodegenerative disease.
    Vajda FJ.
    J Clin Neurosci; 2002 Jan 17; 9(1):4-8. PubMed ID: 11749009
    [Abstract] [Full Text] [Related]

  • 20. Optic disc and visual field changes after trabeculectomy.
    Kotecha A, Spratt A, Bunce C, Garway-Heath DF, Khaw PT, Viswanathan A, MoreFlow Study Group.
    Invest Ophthalmol Vis Sci; 2009 Oct 17; 50(10):4693-9. PubMed ID: 19474409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.